Integra LifeSciences Holdings Corporation (IART) announced the publication of the clinical study, Collagen Conduit Versus Microsurgical Neurorraphy, in the December issue of The Journal of Hand Surgery.
The study, which spanned through two years and covered thirty two patients, primarily focused on NeuraGen Nerve Guide and other traditional methods of direct suture repair in patients who suffered from traumatic nerve injuries. It was a two-year follow up of a controlled, randomized, blind multi-center study of peripheral nerve repair.
All the 32 patients completed the two-year post-operative follow-up period, during which they underwent regular examination of sensory and motor electrophysiological function, post-operative pain assessments and overall hand function.
The results released bring to light some interesting facts. Operation time can be cut down by more than 40% using the collagen conduit than performing direct suture repair. Moreover, patients who were treated with NeuraGen Nerve Guide also reported lower post-operative pain than those treated with direct repair.
NeuraGen Nerve Guide is a semi-permeable bovine collagen tube designed to be used as an interface for damaged nerves and the surrounding tissue.
Integra has been dedicating a lot of its resources towards developing this product, considering the tremendous global potential of the U.S peripherals nerve repair market. The market potential has been estimated at $1.32 to $1.93 billion, by the Magellan Medical Technology Consultants, Inc. (“MMTC”).
IART has already received the FDA clearance for the device in 2001, followed with the CE Mark in Europe in 2003.
Integra is encouraged by the fact that entubulation nerve repair using the NeuraGen Nerve Guide matches the highly-esteemed standard of microsurgical suture. Management is optimistic that the study publication will induce fast adoption of the nerve conduit and will favorably contribute to revenues.
Currently, Integra LifeSciences Holdings Corporation carries a Zacks Rank #3 (Hold). Investors interested in the industry may also consider stocks like Actelion Ltd. (ALIOF), Heska Corp. (HSKA) and Vanda Pharmaceuticals, Inc. (VNDA). All these stocks sport a Zacks Rank #1 (Strong Buy).